These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18398284)

  • 1. The cardiovascular risks of etoricoxib (Arcoxia).
    Sasich LD; Barasain MA; Al Kudsi MA
    Ann Saudi Med; 2008; 28(2):141-2. PubMed ID: 18398284
    [No Abstract]   [Full Text] [Related]  

  • 2. Few options available for arthritis pain relief. FDA declines to approve Merck's Arcoxia.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(10):1020-2. PubMed ID: 17494894
    [No Abstract]   [Full Text] [Related]  

  • 3. Keeping science on top in drug evaluation.
    Avorn J
    N Engl J Med; 2007 Aug; 357(7):633-5. PubMed ID: 17699813
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse effects of etoricoxib: other considerations.
    Kim JA; Choi YS; Kim SH
    Mayo Clin Proc; 2005 Sep; 80(9):1233-4; author reply 1234. PubMed ID: 16178505
    [No Abstract]   [Full Text] [Related]  

  • 5. Discontinuation of Vioxx.
    Garattini S; Bertelé V
    Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
    [No Abstract]   [Full Text] [Related]  

  • 6. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 7. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 8. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 9. Vioxx, the implosion of Merck, and aftershocks at the FDA.
    Horton R
    Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
    [No Abstract]   [Full Text] [Related]  

  • 10. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 11. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 12. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 13. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 14. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
    Einecke D
    MMW Fortschr Med; 2007 Mar; 149(10):18. PubMed ID: 17408040
    [No Abstract]   [Full Text] [Related]  

  • 15. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
    Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS; Fuentealba C; Greenwald M; Brzezicki J; O'Brien K; Soffer B; Polis A; Bird S; Kaur A; Curtis SP;
    J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 18. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy.
    Aldington S; Shirtcliffe P; Weatherall M; Beasley R
    N Z Med J; 2005 Oct; 118(1223):U1684. PubMed ID: 16224508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of Vioxx.
    Kim PS; Reicin AS
    Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669
    [No Abstract]   [Full Text] [Related]  

  • 20. The ever growing story of cyclo-oxygenase inhibition.
    Rodríguez LA; Patrignani P
    Lancet; 2006 Nov; 368(9549):1745-7. PubMed ID: 17113403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.